Cost-Effectiveness Analysis of a Risk-Adapted Algorithm of Plerixafor Use for Autologous Peripheral Blood Stem Cell Mobilization

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 1, 2013, Pages 87-93

  Micallef, Ivana N M ^a   Sinha, Shirshendu ^b   Gastineau, Dennis A ^a   Wolf, Robert ^b   Inwards, David J ^a   Gertz, Morie A ^a   Hayman, Suzanne R ^a   Hogan, William J ^a   Johnston, Patrick B ^a   Lacy, Martha Q ^a   Ansell, Stephen M ^a   Buadi, Francis ^a   Dingli, David ^a   Dispenzieri, Angela ^a   Litzow, Mark R ^a   Porrata, Luis F ^a   Winters, Jeffrey L ^b   Kumar, Shaji ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

Cost effective analysis; Plerixafor; Risk adapted algorithm; Stem cell mobilization

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ALGORITHM; AMYLOIDOSIS; APHERESIS; ARTICLE; CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOMA; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; STEM CELL MOBILIZATION;

ADULT; AGED; ALGORITHMS; CASE-CONTROL STUDIES; COSTS AND COST ANALYSIS; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HETEROCYCLIC COMPOUNDS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PLASMACYTOMA; RISK FACTORS; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84871925730     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.08.010     Document Type: Article

References (29)

1. Gertz M.A., Wolf R.C., Micallef I.N., Gastineau D.A. Clinical impact and resource utilization after stem cell mobilization failure in patients with multiple myeloma and lymphoma. Bone Marrow Transplant 2010, 45:1396-1403.
2. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
3. Blystad A.K., Delabie J., Kvaløy S., et al. Infused CD34 cell dose, but not tumour cell content of peripheral blood progenitor cell grafts, predicts clinical outcome in patients with diffuse large B-cell lymphoma and follicular lymphoma grade 3 treated with high-dose therapy. Br J Haematol 2004, 125:605-612.
4. Bolwell B.J., Pohlman B., Rybicki L., et al. Patients mobilizing large numbers of CD34+ cells ('super mobilizers') have improved survival in autologous stem cell transplantation for lymphoid malignancies. Bone Marrow Transplant 2007, 40:437-441.
5. Gordan L.N., Sugrue M.W., Lynch J.W., et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003, 44:815-820.
6. Limat S., Woronoff-Lemsi M.C., Deconinck E., et al. Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study. Bone Marrow Transplant 2000, 25:997-1002.
7. O'Shea D., Giles C., Terpos E., et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006, 37:731-737.
8. Toor A.A., Ayers J., Strupeck J., et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol 2004, 124:769-776.
9. De Clercq E. The AMD3100 story: the path to the discovery of a stem cell mobilizer (Mozobil). Biochem Pharmacol 2009, 77:1655-1664.
10. DiPersio J.F., Uy G.L., Yasothan U., Kirkpatrick P. Plerixafor. Nat Rev Drug Discov 2009, 8:105-106.
11. DiPersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
12. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
13. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
14. Micallef I.N., Stiff P.J., DiPersio J.F., et al. Successful stem cell remobilization using plerixafor (mozobil) plus granulocyte colony-stimulating factor in patients with non-Hodgkin lymphoma: results from the plerixafor NHL phase 3 study rescue protocol. Biol Blood Marrow Transplant 2009, 15:1578-1586.
15. Brave M., Farrell A., Ching Lin S., et al. FDA review summary: mozobil in combination with granulocyte colony-stimulating factor to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation. Oncology 2010, 78:282-288.
16. Burgstaler E.A., Pineda A.A., Winters J.L. Hematopoietic progenitor cell large volume leukapheresis (LVL) on the Fenwal Amicus blood separator. J Clin Apher 2004, 19:103-111.
17. Burgstaler E.A., Pineda A.A. The negative effect of high peripheral white blood cell count on CD34+ cell recovery. J Clin Apher 2002, 17:148.
18. Burgstaler E.A., Pineda A.A., Winters J.L. Effects of high whole blood flow rates and high peripheral white blood cell counts on CD34+ yield and cross-cellular contamination. Cytotherapy 2003, 5:446.
19. Burgstaler E.A., Winters J.L. Manual color monitoring to optimize hematopooietic progenitor cell collection on the Fenwal Amicus. J Clin Apher 2011, 26:123-130.
20. Sinha S., Gastineau D., Micallef I., et al. Predicting PBSC harvest failure using circulating CD34 levels: developing target-based cutoff points for early intervention. Bone Marrow Transplant 2011, 46:943-949.
21. Micallef I., Ansell S.M., Buadi F., et al. A risk adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. ASH Annual Meeting Abstracts 2009, 114:3211.
22. Micallef I.N., Inwards D.J., Dispenzieri A., et al. A risk adapted approach utilizing plerixafor in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2010, 16:S197-S198.
23. Micallef I.N., Sinha S., Gastineau D.A., Wolf R., Inwards D.J., Gertz M.A., Hayman S.R., Hogan W.J., Johnston P.B., Lacy M.Q., Ansell S.M., Buadi F., Dingli D., Dispenzieri A., Litzow M.R., Porrata L.F., Winters J.L., Kumar S. A cost effective analysis of a risk-adapted algorithm for plerixafor use in autologous peripheral blood stem cell mobilization. Biol Blood Marrow Transplant 2011 Feb, 17(Suppl 2):S159-S160.
24. Stiff P.J., Micallef I., Nademanee A.P., et al. Transplanted CD34(+) cell dose is associated with long-term platelet count recovery following autologous peripheral blood stem cell transplant in patients with non-Hodgkin lymphoma or multiple myeloma. Biol Blood Marrow Transplant 2011, 17:1146-1153.
25. Micallef I.N., Stiff P., Stadtmauer E., et al. Similar 1 year survival of patients receiving plerixafor (Mozobil) plus G-CSF versus placebo plus G-CSF mobilized autologous grafts: results from two phase 3 randomized trials in patients with NHL or MM undergoing autologous transplantation after front-line or rescue mobilization. ASH Annual Meeting Abstracts 2009, 114:2319.
26. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
27. Li J., Hamilton E., Vaughn L., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
28. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012, 52:55-62.
29. Kymes S.M., Pusic I., Lambert D.L., Gregory M., Carson K.R., DiPersio J.F. Economic evaluation of plerixafor for stem cell mobilization. Am J Manag Care 2012, 18:33-41.